title: IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months.
abstract: Multiple sclerosis (MS) is presumed to be a T-cell mediated chronic inflammatory disease of the central nervous system. We have previously reported that IFN-beta 1b (Betaseron) decreases CD3-mediated TNF-alpha secretion but increases another inflammatory cytokine, IL-6 after three months of treatment. We have now examined cytokine secretion of peripheral blood mononuclear (PMNC) cells after stimulation with OKT3 (anti-CD3) monoclonal antibody (mAb) or Con A in subjects with clinically stable relapsing MS before and three, six and nine months after initiating IFN-beta 1b treatment. At nine months Con A-induced TNF-alpha secretion decreased significantly below baseline but IFN-gamma secretion increased above baseline. There were no significant changes in Con A-induced IL-4 over the six month period and no changes in IL-10 and IL-2 over the nine month period. After nine months on treatment the CD3-induced TNF-alpha and IFN-gamma secretion was not significantly different from the original baseline values. Increased CD3-mediated IL-6 secretion in on-treatment compared to pre-treatment samples at three months gradually declined to baseline values by nine months on-treatment. There was no significant changes from baseline compared to nine months on-treatment in CD3-mediated IL-2, IL-4, IL-10. IFN-beta 1b (Betaseron) treatment has no clear persistent effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion.
authors.affiliation: Department of Neurology, University of Texas-Houston 77225, USA.
authors.forename: S A
authors.initials: SA
authors.lastname: Brod
authors.forename: L D
authors.initials: LD
authors.lastname: Nelson
authors.forename: M
authors.initials: M
authors.lastname: Khan
authors.forename: J S
authors.initials: JS
authors.lastname: Wolinsky
mesh_terms: D000328:Adult; D017252:CD3 Complex / Q000276:immunology*; D003208:Concanavalin A; D016207:Cytokines / Q000378:metabolism*; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D016899:Interferon-beta / Q000009:adverse effects* / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000378:metabolism; D007378:Interleukins / Q000378:metabolism; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D012008:Recurrence; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D017252:CD3 Complex; D016207:Cytokines; D007378:Interleukins; D014409:Tumor Necrosis Factor-alpha; D003208:Concanavalin A; D016899:Interferon-beta; D007371:Interferon-gamma